Amicus Therapeutics (NASDAQ:FOLD) Upgraded by StockNews.com to “Buy”
StockNews.com upgraded shares of Amicus Therapeutics (NASDAQ:FOLD – Free Report) from a hold rating to a buy rating in a report published on Monday. Several other equities analysts have also weighed in on the stock. Cantor Fitzgerald restated an overweight rating and set a $20.00 price target on shares of Amicus Therapeutics in a research […]
More Stories
LandBridge (NYSE:LB) PT Raised to $43.00 at The Goldman Sachs Group
LandBridge (NYSE:LB – Get Free Report) had its target price upped by stock analysts at The Goldman Sachs Group from...
Meta Platforms (NASDAQ:META) Earns Overweight Rating from Cantor Fitzgerald
Cantor Fitzgerald reaffirmed their overweight rating on shares of Meta Platforms (NASDAQ:META – Free Report) in a research report report...
BlackRock Innovation and Growth Term Trust (NYSE:BIGZ) Major Shareholder Purchases $42,024.93 in Stock
BlackRock Innovation and Growth Term Trust (NYSE:BIGZ – Get Free Report) major shareholder Saba Capital Management, L.P. purchased 5,581 shares...
Insider Selling: Arteris, Inc. (NASDAQ:AIP) VP Sells 3,615 Shares of Stock
Arteris, Inc. (NASDAQ:AIP – Get Free Report) VP Paul L. Alpern sold 3,615 shares of the company’s stock in a...
JPMorgan Chase & Co. Raises Rocket Companies (NYSE:RKT) Price Target to $19.00
Rocket Companies (NYSE:RKT – Free Report) had its target price lifted by JPMorgan Chase & Co. from $15.00 to $19.00...
Cantor Fitzgerald Reaffirms “Neutral” Rating for Snap (NYSE:SNAP)
Cantor Fitzgerald reissued their neutral rating on shares of Snap (NYSE:SNAP – Free Report) in a report released on Monday...